Delgado HC, Mendizábal GR, Acosta GR, Ayala AA, Reyes SG, Jiménez JM

Language: Spanish
References: 19
Page: 73-77
PDF size: 171.06 Kb.

ABSTRACT

Among the tumors of the central nervous system, those that are composed of double tumoral component (glial component and mesenchimal component) are called gliomesenchimal tumors, the most frequent of these tumors is the gliosarcoma, this tumor is characterized for is double tumoral component that as the same malignant behavior, this leads to an elevated rate of mortality, with a life expectation of 4 to 6 months. This tumor is more frequent in men than in women by 1.8-3:1 and age average of 40-60 years. We report a case and revision of the literature with the objective of to differentiate de characteristics that separate the gliosarcoma from the classic glioblastoma, with and incidence of 2% of all the glioblastomas.

REFERENCES

1. Lutterbach J, Guttenberger R, Pagenstecher A. Gliosarcoma: a clinical study. Radiotherapy Oncol 2001; 61: 57-64.

2. Galaniz E, Buckner CJ. Clinic outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer treatment Group results. J Neurosurgery 1998; 425-30.

3. Sreenan JJ, Prayson RA. Gliosarcoma. A study of 13 tumors, including p53 and CD 34 inmunohistochemistry. Arch Pathol Lab Med. 1997; 121(2): 129-33.

4. Sade B, Prayson AR, Lee HJ. Gliosarcoma with infratemporal extension. J Neurosurgery 2006; 105: 904-7.

5. Kim DS, Kang SK, Chi JG. Gliosarcoma: A case with unusual epithelial feature. J Korean Med Sci 1999; 14: 345-50.

6. Kleihues P, Webster KC (eds.). Tumours of the Nervous System. Pathology and genetics. World Health Organization Classification of Tumours. Lyon: IARC; 2000, p. 42-4.

7. Ho KL. Histogenesis of sarcomatous component of the gliosarcoma: an ultrastructural study. Acta Neuropathol 1990; 81: 178-88.

8. Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, et al. The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol 1996; 55: 973-81.

9. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohaki H. Genetic profile of gliosarcoma. Am J Pathol 2000; 156(2): 425-32.

10. Lutterbach J, Guttenberger R, Pagenstecher A. Gliosarcoma: a clinical study. Radiother Oncol 2001; 61: 57-64.

11. Ohgaki H, Biernat W, Reis R, Hegi M, Kleihues P. Gliosarcoma. In: Kleihues P, Cavenee WK (eds.). Pathology and genetics of tumors of the nervous system. Lyon: IARC Press; 2000, p. 42-4.

12. Actor B, Cobbers JMJL, Buschges R, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 2002; 34: 416-27.

13. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-24.

14. Ozolek JA, Finkelstein SD, Couce ME. Gliosarcoma with epithelial differentiation: immunohistochemical and molecular characterization. A case report and review of the literature. Mod Pathol 2004; 17: 739-45.

15. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME. Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol 1995; 54: 651-6.

16. Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L. Gliosarcomas: analysis of 11 cases do two subtypes exist? J Neurooncol 2005; 74: 59-63.

17. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 1998; 89: 425-30.

18. Buckner JC, Schomberg PJ, McGinnis WL, et al. Phase III study of radiation therapy (RT) plus BCNU with or without recombinant interferon alpha (IFN) in high grade glioma: an NCCTG study. Proc Am Soc Clin Oncol 1997; 16: 385a (Abstract).

19. Richman AV, Balis GA, Maniscalco JE. Primary intracerebral tumor with mixed chondrosarcoma and glioblastomagliosarcoma or sarcoglioma. J Neuropathol Exp Neurol 1980; 39: 329-35.